Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
56 | Publisher: Huidian Research
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Research and Investment Prospect of Human Vaccine Industry in China, 2014-2018, mainly studies the market, competition pattern and segmentations of human vaccine industry in China and analyzes the industry chain, import & export and key enterprises of human vaccine in China. This report analyzes the business performances of 7 key enterprises, including Beijing Tiantan Biological Products Co., Ltd, ChongQing ZhiFei Biological Products Co., Ltd, Walvax Biotechnology Co., Ltd, Liaoning Chengda Co., Ltd (LCD) etc. As one of powerful vaccine manufacturing countries in world, China has 42 vaccine manufacturers with approval license. In 2013, the total of lot release quantity of vaccines was about 755 million doses, increasing by 0.53% over the 751 million doses in 2012. Vaccine manufacturers mainly consist of state-owned enterprises, private enterprises and foreign-funded enterprises in China. Seeing from the lot release quantity of vaccine in 2013, the state-owned enterprises still take the leading position in vaccine market, with market shares of 62%, followed by private enterprises and foreign-funded enterprises successively, with market shares of 33.77% and 4.23% respectively. Most of market of typeⅠvaccines is still dominated by state-owned enterprises, including 6 largest institutes of China National Biotec-Group Company Limited and Changchun Keygen Biological Products Co., Ltd. Private enterprises take half of market shares of typeⅡvaccines, the representative enterprises include: ChongQing ZhiFei Biological Products Co., Ltd, and Walvax Biotechnology Co., Ltd etc. While the international enterprises have definite advantages in respects of high-end vaccines and multivalent vaccines, taking pneumococcal vaccines for instance, only one conjugate vaccine is available, say: Pneumococcal 7-Valent Conjugate Vaccine produced by Pfizer. Although, at present, several enterprises are conducting studies on pneumococcal conjugate vaccines, it is still long to launch on the market, with huge uncertainties. In 2014-2018, the average growth rate of vaccine in China will maintain at 16%-18%. The main driving factors include: implement of national vaccine immunization plan, increasing receptivity of vaccine by people, rising trend of initiative vaccination and increase of type Ⅱvaccines application etc. It can be expected that the market scale of vaccine will hit CNY 40.5 billion in 2018.
Table of Contents 1. Overview of Human Vaccine Industry 1.1 Definition and Characteristics 1.1.1 Industry Definition 1.1.2 Product Classification 1.2 Industry Chain 1.2.1 Upstream Market 1.2.2 Downstream Market 2. Development Environment of Human Vaccine in China 2.1 Policy Environment 2.2 Technical Environment 2.2.1 R&D of Vaccines Technology in China 2.2.2 Hot Technologies Analysis 2.2.3 Active Degree of Industry Technology 3. Development of Human Vaccine Industry 3.1 Development Status Quo of Human Vaccine 3.1.1 Overview of Market 3.1.2 Supply in 2013 3.2 Demand of Human Vaccine 3.2.1 Demand in 2013 3.2.2 Demand Forecast, 2014-2018 3.3 Competition Pattern 4. Import and Export of Human Vaccine Industry in China 4.1 Import 4.1.1 Import Data 4.1.2 Import Sources, Jan.-Sept 2014 4.2 Export 4.2.1 Export Data 4.2.2 Export Destinations, Jan.-Sept 2014 5. Segmented Industries of Human Vaccine 5.1 Epidemic Meningitis Vaccine 5.1.1 Industry Status Quo 5.1.2 Segmentations 5.2 Hepatitis B Vaccine 5.2.1 Market Status Quo 5.2.2 Supply 5.2.3 Demand 5.3 Hepatitis A Vaccine 5.3.1 Supply 5.3.2 Demand 5.4 Encephalitis B Vaccine 5.4.1 Supply 5.4.2 Demand 5.5 DPT Vaccine 5.5.1 Supply 5.5.2 Demand 5.6 Influenza Vaccine 5.6.1 Supply 5.6.2 Demand 5.7 Rabies Vaccine 5.7.1 Overview of Market 5.7.2 Supply 5.7.3 Demand 5.8 Pneumococcal Vaccine 5.8.1 Supply 5.8.2 Demand 6. Key Human Vaccine Enterprises in China 6.1 Beijing Tiantan Biological Products Co., Ltd 6.1.1 Company Profile 6.1.2 Business Performance 6.1.3 Vaccine Business 6.2 Hualan Biological Engineering Inc. 6.2.1 Company Profile 6.2.2 Business Performance 6.2.3 Vaccine Business 6.3 Liaoning Chengda Co., Ltd (LCD) 6.3.1 Company Profile 6.3.2 Business Performance 6.3.3 Vaccine Business 6.4 Walvax Biotechnology Co., Ltd 6.4.1 Company Profile 6.4.2 Business Performance 6.4.3 Vaccine Business 6.5 ChongQing ZhiFei Biological Products Co., Ltd 6.5.1 Company Profile 6.5.2 Business Performance 6.5.3 Vaccine Business 6.6 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd 6.6.1 Company Profile 6.6.2 Vaccine Business 6.7 Changchun BCHT Biotechnology Co., Ltd 6.7.1 Company Profile 6.7.2 Vaccine Business 7. Investment Analysis on Human Vaccine 7.1 Investment Opportunities 7.1.1 Policy Support 7.1.2 Vast Consumption Market 7.2 Investment Risks 7.2.1 Market Competition 7.2.2 Quality Accidents 7.2.3 Product R&D 7.2.4 Core Technician Drain 7.3 Entry Barrier 7.3.1 Administrative Barrier 7.3.2 Capital Barrier 7.3.3 Technical Renovation Barrier 7.4 Development Trend of Human Vaccine Industry 7.4.1 International Blockbuster Products Will be Innovation Goal of Chinese Enterprises 7.4.2 Chinese-foreign Joint Venture Will Become Important Enterprise Development Mode 7.4.3 Children Conjugate Vaccine Will Become Trend
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
